RBS: With the approval of Ellavie in Sweden last week, ACR has demonstrated its ability to deliver on milestones. It is this consistent performance that sees us rate it as a stand-out stock in the life science sector.
RBS have increased their price target to A$4.06 (from A$3.88). Buy retained.
bby increases acr target to $4.10, page-2
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
